GlassScriptPhysician profile
Sam Winters Richwine
NPI 1386753564
$565.71
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $159 · 2020: $223 · 2021: $118 · 2022: $66.12.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $182.42 | 2019-2021 | |
| Smith+Nephew, INC. | $135.57 | 2019-2021 | |
| Depuy Synthes Sales INC. | $91.90 | 2020-2021 | |
| Tela Bio, INC. | $66.12 | 2022 | |
| Integra Lifesciences Corporation | $48.96 | 2020 | |
| Osiris Therapeutics INC. | $14.59 | 2019 | |
| Mentor Worldwide LLC | $13.59 | 2019 | |
| Medline Industries LP | $12.56 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Richwine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.